Curated News
By: NewsRamp Editorial Staff
June 26, 2025

Scinai's PC111 Research Wins Prestigious Dermatology Award

Reddit Discuss on LinkedIn Discuss on Substack participate in discussion on bluesky Participate in discussion on Mastodon View History of this news story on GitHub
Original Source

TLDR

  • Scinai Immunotherapeutics gains a competitive edge with Dr. Roberta Lotti's award-winning research on PC111, a potential breakthrough for autoimmune skin conditions.
  • PC111, developed by Pincell Srl and optioned by Scinai, works by blocking soluble Fas Ligand to prevent blister formation in pemphigus vulgaris.
  • The advancement of PC111 by Scinai Immunotherapeutics offers hope for a non-immunosuppressive treatment, improving lives affected by severe autoimmune skin diseases.
  • Discover how Scinai Immunotherapeutics is pioneering a novel treatment for pemphigus vulgaris with PC111, a first-in-class anti-Fas Ligand monoclonal antibody.

Impact - Why it Matters

This news is significant as it highlights a potential breakthrough in the treatment of pemphigus vulgaris, a painful and debilitating autoimmune skin disease. The recognition of PC111's research with the "Oscar of Italian Dermatology" underscores its innovative approach to blocking disease progression without suppressing the immune system, offering hope for safer and more effective treatments. For investors and the biotech community, Scinai's progress with PC111 and its strategic option to acquire Pincell Srl represents a noteworthy development in the biopharmaceutical sector, with implications for future therapies in immunology and inflammation.

Summary

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company specializing in inflammation and immunology, has announced a significant achievement by Dr. Roberta Lotti of Pincell Srl, who received the prestigious "Oscar of Italian Dermatology" from SIDeMaST. This accolade was awarded for her groundbreaking research on PC111, a pioneering anti-Fas Ligand monoclonal antibody. The study, titled "Blocking soluble Fas Ligand ameliorates pemphigus", highlights PC111's potential to prevent blister formation by inhibiting keratinocyte apoptosis in pemphigus vulgaris, a severe autoimmune skin condition. Scinai Immunotherapeutics holds an option to acquire Pincell and is advancing PC111 as a lead asset, underscoring its promise as a non-immunosuppressive, disease-modifying treatment. For more details, the full press release can be viewed here.

Scinai operates through two main business units: one dedicated to the in-house development of innovative biological therapeutic products, including a pipeline of nanosized VHH antibodies ("NanoAbs") targeting diseases with unmet medical needs, and another offering comprehensive CDMO services to early-stage biotech companies. More information about Scinai's endeavors can be found on their website.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Scinai's PC111 Research Wins Prestigious Dermatology Award

blockchain registration record for this content.